VITL secures $7.5M amid GLP-1 surge to transform cash-pay clinic prescriptions

The rapid rise of med-spas, weight-loss clinics, and concierge medical practices — where patients typically pay membership fees for direct, often same-day access to doctors — has created new demand for specialised healthcare tools. Despite operating outside traditional insurance systems, many of these providers still rely on legacy software designed for insurance-based care.

VITL, an 18-month-old startup, says it is addressing one of the biggest technological bottlenecks in this space by building an e-prescribing platform tailored specifically for cash-pay medical businesses.

On Wednesday, the company announced it has secured $7.5 million in a Series A funding round led by SignalFire.

Founder and CEO Charlie Jordan launched the Nashville-based company after recognising how much time healthcare providers spend managing prescriptions for treatments not covered by insurance.

In many cases, clinics still rely on outdated methods like fax or phone calls to send prescriptions to compounding pharmacies that create customised medications. This process often lacks transparency, leaving providers unaware of final costs or fulfilment timelines.

VVITL's platform aims to streamline this workflow by connecting clinics to a nationwide network of compounding pharmacies. It offers real-time price comparisons and order tracking, similar to e-commerce platforms. We shortened the prescription time from several minutes down to a few seconds," Jordan said, highlighting the efficiency gains for clinics that process dozens of prescriptions daily. According to the company, its technology can save clients up to two full workdays each month by automating what has traditionally been a slow and opaque process.

The traction has been notable. Just over a year since launch, VITL reports onboarding more than 630 clinics and reaching eight figures in annualised recurring revenue, indicating it is on track to generate at least $10 million annually. Even so, the current customer base represents only a small portion of the broader U.S. market, which includes tens of thousands of clinics. Growth is expected to accelerate as demand for treatments such as GLP-1 drugs — including Ozempic and Wegovy — peptides, and aesthetic procedures like Botox increases.

VITL did not initially pitch SignalFire, but SignalFire's rapid expansion drew the firm's attention, which is known for using data and AI to identify high-growth startups. That interest ultimately led to the $7.5 million investment. The company competes in part with Surescripts, a long-standing player in the e-prescribing space, as well as with platforms like Jane Software that include prescription tools within broader electronic health record systems.

VITL says its key differentiator is its dedicated focus on the unique workflows and operational needs of cash-pay healthcare providers. This segment continues to expand as patient preferences evolve.